EMVision Medical Devices (ASX:EMV) shipped an emu brain scanner to a second US pivotal validation trial site, the Mayo Clinic in Jacksonville, Florida, according to a Monday Australian bourse filing.
The site initiation visit and training are scheduled to begin in early May, the filing said.
The site initiation visit and device training visit at its first US site, the University of Texas Health Science Center at Houston Medical School and Memorial Hermann-Texas Medical Center, is scheduled for this week.
The primary goal of the trial is to demonstrate haemorrhage detection sensitivity and specificity of greater than 80%, supporting the device's registration with the US Food and Drug Administration.
It plans to initiate further trial sites in the US and Australia.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。